ISRCTN27020581进行中（未招募）1 期
Phase I trial Quotient code: QSC206365 [The full scientific title will be published within30 months after the end of the trial]
Relay Therapeutics (United States)0 个研究点目标入组 6 人开始时间: 2022年7月5日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
排除标准
- •The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
研究者
相似试验
进行中（未招募）
1 期
Phase I trial Quotient Code: QSC206680Healthy volunteersISRCTN12656966Emplicure AB12
进行中（未招募）
1 期
Phase I trial Quotient Code QSC202600Healthy VolunteersISRCTN10603388Alterity Therapeutics Limited6
已完成
1 期
Phase I trial Quotient Code: QSC207682The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.Not SpecifiedISRCTN10750305Constellation Pharmaceuticals (United States)8
进行中（未招募）
1 期
Phase I trial, Quotient code: QSC205601The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record when the results are published, which will be within 30 months after the trial has ended.ISRCTN10521680ovartis (Switzerland)116
进行中（未招募）
1 期
Phase I trial, Quotient Code: QSC208063The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.ISRCTN17473850Trevena, Inc.72